论文部分内容阅读
目的探讨血清糖类抗原125(CA125)和激肽释放酶10(hk10)在上皮性卵巢癌中的表达及其在紫杉醇联合顺铂(TP)化疗方案疗效评估中的作用。方法 36例上皮性卵巢癌患者第1天24 h静脉滴注紫杉醇135 mg·m-2,第2,3天静脉滴注顺铂75 mg·m-2。酶联免疫吸附法(ELISA)检测36例上皮性卵巢癌患者及27例良性卵巢肿瘤患者血清CA125及hk10水平,分析2组患者CA125、hk10水平。同时检测28例卵巢癌患者TP化疗前后CA125和hk10水平变化及其与化疗疗效的相关性。结果卵巢癌组患者血清CA125及hk10水平显著高于良性卵巢肿瘤组(P均<0.05)。28例卵巢癌患者接受TP方案化疗,完全缓解(CR)4例,部分缓解(PR)11例,稳定(SD)3例,进展(PD)10例,客观缓解率为64.3%。CR组化疗后CA125及hk10水平显著低于SD及PD组(P<0.05)。结论卵巢癌患者血清CA125和hk10水平显著升高,可以作为TP方案化疗疗效的评估指标。
Objective To investigate the expression of serum carbohydrate antigen 125 (CA125) and kallikrein 10 (hk10) in epithelial ovarian cancer and their effects on the efficacy of paclitaxel plus cisplatin (TP) chemotherapy regimen. Methods Thirty-six patients with epithelial ovarian cancer were injected intravenously with paclitaxel 135 mg · m -2 at 24 h on the first day and 75 mg · m -2 cisplatin intravenously on the second and third day. The serum levels of CA125 and hk10 in 36 patients with epithelial ovarian cancer and 27 patients with benign ovarian tumor were detected by enzyme-linked immunosorbent assay (ELISA), and the levels of CA125 and hk10 were analyzed. At the same time, the changes of CA125 and hk10 levels in 28 patients with ovarian cancer before and after TP chemotherapy and their correlation with the curative effect of chemotherapy were also detected. Results The levels of serum CA125 and hk10 in ovarian cancer patients were significantly higher than those in benign ovarian cancer patients (all P <0.05). Twenty-eight patients with ovarian cancer underwent TP regimen. Four patients achieved complete remission (CR), partial response (PR) in 11, stable (SD) in 3 and progression (PD) in 10. The objective response rate was 64.3%. The levels of CA125 and hk10 in CR group were significantly lower than those in SD and PD groups (P <0.05). Conclusion Serum levels of CA125 and hk10 in patients with ovarian cancer are significantly increased, which can be used as an evaluation index for the efficacy of TP chemotherapy.